1.
Rev Med Suisse
; 4(141): 200, 202-4, 206-8 passim, 2008 Jan 23.
Article
in French
| MEDLINE
| ID: mdl-18335885
ABSTRACT
In 2008 three biological agents against TNFalpha will be available. The combination of infliximab with azathioprine is no longer recommended, as hepatosplenic lymphomas with a particularly bad prognosis have been associated with this combined therapy. Regular maintenance therapy with infliximab is as effective in preventing the development of anti-infliximab antibodies as co-administration of this anti-TNFalpha agent with an immunomodulator. The benefit of regular maintenance therapy is probably linked to the presence of residual trough levels of infliximab between perfusions.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Irritable Bowel Syndrome/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Antibodies, Monoclonal, Humanized , Certolizumab Pegol , Colitis, Ulcerative/drug therapy , Crohn Disease/drug therapy , Crohn Disease/surgery , Humans , Immunoglobulin Fab Fragments/therapeutic use , Immunologic Factors/therapeutic use , Infliximab , Polyethylene Glycols/therapeutic use
2.
Rev Med Suisse
; 3(95): 201-2, 204-6, 208-14, 2007 Jan 24.
Article
in French
| MEDLINE
| ID: mdl-17357689
ABSTRACT
There was no real therapeutic advances in inflammatory bowel diseases last year. In addition to infliximab, new anti-TNF-alpha agents will soon become available.